Adial submits AD04 application for FDA Commissioner's National Priority Voucher pilot program
PUBT · 04/27 12:47
Share
Listen to the news
- Adial Pharmaceuticals submitted an application to FDA Commissioner’s National Priority Voucher (CNPV) pilot program for its AD04 development program.
- CNPV, if granted, could allow an accelerated FDA review timeline of about 1-2 months once complete materials are submitted, versus standard 10-12 months.
- Voucher, if awarded, cannot be transferred or sold.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270847PRIMZONEFULLFEED9696612) on April 27, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved